Solid Biosciences Inc (SLDB) - Business Payback Period

Corporate emblem and logo of Solid Biosciences Inc (SLDB)

The strategy of Solid Biosciences Inc. (SLDB) is based on outsourcing clinical trials to external contractors while maintaining full control over its own patents. This P/E ratio chart, which currently stands at -3.90, complements data regarding the dependence of success on government funding and the safety of new drugs. Solid Biosciences Inc. (SLDB) is currently developing gene therapies for rare pathologies, relying on grants and advances due to negative cash flow.

solidbio.com - SLDB Price to Earnings Ratio (period 07/04/2022 - 11/12/2026)

Comprehensive metric breakdowns and analytics for Solid Bio (SLDB)

- stock quotes and analyst forecast:
Price Chart solidbio.com|SLDB - Analyst Consensus Forecast
- market capitalization indicators:
Market Capitalization Solid Biosciences Inc.|SLDB - Enterprise Value
- book capitalization data:
Equity per Share Solid Biosciences|SLDB - Company Net Assets|Market Value to Book Value solidbio.com|SLDB - Company Total Assets
- debt and solvency information:
Debt to Equity Solid Biosciences Inc.|SLDB - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Solid Corp|SLDB - Company Debts|Debts to Book Value Solid Biosciences Inc.|SLDB - Company Long-Term Debt|Short-Term Debt Volume Solid Biosciences|Quick Liquidity Indicator solidbio.com
- financial results and valuation multiples details:
SLDB - Net Profit|Company Profit Forecast Solid Biosciences Inc.|SLDB - P/E Multiple|Projected Price to Earnings Ratio Solid Biosciences Inc|SLDB - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Solid Biosciences Inc.|SLDB - Operating profit EBITDA|Net earnings per share for the last 12 months Solid Biosciences|SLDB - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months solidbio.com|SLDB - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Solid Biosciences Inc.
Comprehensive company analysis:SLDB (solidbio.com)
Brand item of Solid Biosciences Inc.

The P/E ratio measures the investment payback period through the ratio of market value to net income. By analyzing the P/E volatility of a company, an investor can identify the risk of a "value trap" during a decline in returns. For Solid Biosciences Inc. (SLDB), this metric is critical, as outsourcing production to third-party contractors creates a dependency of margins on partners. The stability of this indicator confirms the viability of the R&D model and the resilience of the business.

Analysis of competing companies

Price to Earnings Ratio TEM|P/E Multiple QGEN|Business Payback Period Ionis Pharmaceuticals, Inc.|P/E Multiple RGEN (Repligen Corp.)|RNA: Price to Earnings Multiple|CRSP: Price to Earnings Ratio|Company Value to Net Income WGS (genedx.com)|RARE: P/E Multiple|BEAM (Beam Therapeutics Inc) - Price to Earnings Ratio|SRPT (Sarepta Therapeutics Inc) - P/E Multiple|Twist Bioscience Corp (TWST) - Business Payback Period|Price to Earnings Ratio 10x Genomics, Inc. (TXG)|NTLA - Market Cap to Earnings|Price to Earnings Ratio Stoke Therapeutics, Inc. STOK|Business Payback Period BioLife Solutions Inc (BLFS)|Wave Life Sciences Corp - P/E Multiple|Maze Therapeutics Corp (MAZE) - Price to Earnings Ratio|SION: P/E Multiple|PRME - Business Payback Period|TSHA (Taysha Gene Therapies, Inc.) - P/E Multiple|Market Cap to Earnings uniQure NV QURE|Price to Earnings Ratio MeiraGTx PLC (MGTX)|REGENXBIO Corp - Price to Earnings Multiple|P/E Multiple OCGN (Ocugen, Inc.)|PACB - Price to Earnings Ratio|Benitec Biopharma - P/E Multiple|Market Cap to Earnings Design Therapeutics Inc|Rocket Pharmaceuticals Inc (RCKT) - Price to Earnings Ratio|FDMT - Business Payback Period|Price to Earnings Ratio LXEO|KRRO: Company Value to Net Income|P/E Multiple EDIT|Business Payback Period Silence Therapeutics PLC|Price to Earnings Ratio ProQR Therapeutics PRQR|CDXS: Price to Earnings Multiple|Sangamo Therapeutics - P/E Multiple|Nautilus Biotechnology (NAUT) - Price to Earnings Ratio|MGX (Metagenomi) - Price to Earnings Ratio|DTIL - Business Payback Period|Price to Earnings Ratio Generation Bio Co|Boundless Bio Inc (BOLD) - Business Payback Period|Price to Earnings Ratio Exicure, Inc. (XCUR)|Price to Earnings Ratio IMNN (imunon.com)|P/E Multiple PHIO (Phio Pharmaceuticals Corp.)|MBIO: Price to Earnings Multiple|TransCode - P/E Multiple|BNGO: Price to Earnings Ratio|APDN: P/E Multiple|Price to Earnings Multiple BLUE|Price to Earnings Ratio ImmunoPrecise Antibodies Ltd|Price to Earnings Multiple OMGA (Omega Therapeutics Inc)|P/E Multiple OMIC|P/E Multiple Regulus (RGLS)|Price to Earnings Ratio Syros Pharmaceuticals SYRS|Business Payback Period telesisbio.com (TBIO)|TCON - Price to Earnings Ratio|Market Cap to Earnings Unity Biotechnology Inc.